SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study

In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. No real-life data on genotype 3 (GT3) cirrhotic pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangia, Alessandra, Cenderello, Giovanni, Copetti, Massimiliano, Verucchi, Gabriella, Piazzolla, Valeria, Lorusso, Celeste, Santoro, Rosanna, Squillante, Maria Maddalena, Orlandini, Alessandra, Minisini, Rosalba, Ciancio, Alessia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523403/
https://www.ncbi.nlm.nih.gov/pubmed/30987413
http://dx.doi.org/10.3390/cells8040313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523403/
https://www.ncbi.nlm.nih.gov/pubmed/30987413
http://dx.doi.org/10.3390/cells8040313

Ejemplares similares